Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Ofloxacin for prevention of bacterial infections in granulocytopenic patients

Prophylaxe bakterieller Infektionen durch Ofloxacin bei granulozytopenischen Patienten

  • 19 Accesses

  • 24 Citations


We studied the potential value of oral ofloxacin (200 mg twice daily) for selective decontamination and infection prevention in 40 granulocytopenic patients with acute leukemia, blast crisis of chronic myelogenous leukemia, hairy cell leukemia or severe aplastic anemia. The quality of selective decontamination was acceptable with rapid elimination of Enterobacteriaceae from the alimentary tract, only a slight decrease in concentrations of anaerobes in faeces, and a small number of newly acquired transient (twelve isolates in seven patients) or colonizing (six strains with 28 isolates in four patients) aerobic gram-negative rods andStaphylococcus aureus (one isolate) recovered from 672 surveillance cultures from faeces, oral washings and urine. Two of three patients colonized with ofloxacin-resistantPseudomonas aeruginosa strains developed Pseudomonas infections. A total of twelve acquired infections was observed. Six were microbiologically documented infections, all caused by ofloacin-resistant bacteria (twoP. aeruginosa, twoStaphylococcus epidermidis, oneAerococcus viridans, oneMicrococcus sp.). Tolerance was acceptable with no serious side effects observed. Mean drug concentrations in serum and saliva were comparable to those determined in healthy volunteers and were found to be higher in saliva than in serum. We conclude that ofloxacin may be studied as an effective alternative to trimethoprim-sulfamethoxazole for selective decontamination and infection prevention in severely granulocytopenic patients. Careful monitoring of colonizingPseudomonas spp. with decreased ofloxacin sensitivity, however, seems necessary.


Der Wert einer Behandlung mit Ofloxacin (2 × 200 mg täglich) für die sogenannte selektive Dekontamination und Infektionsprophylaxe bei Granulozytopenie wurde bei 40 Patienten mit akuter Leukämie, akuter Phase einer CML, Haarzell-Leukämie oder schwerer aplastischer Anämie untersucht. Es kam zu einer akzeptablen Qualität der selektiven Dekontamination mit Elimination von Enterobacteriaceae in der Darmflora und einer nur geringen Verringerung in der Anaerobier-Konzentration im Stuhl. Die Auswertung von 672 Überwachungskulturen aus Rachenspülung, Stuhl und Urin zeigte eine kleine Zahl von neu entdeckten transienten (zwölf Isolate bei sieben Patienten) oder kolonisierenden (sechs Stämme mit 28 Isolaten bei vier Patienten) aeroben gramnegativen Bakterien und vonStaphylococcus aureus (ein Isolat). Zwei von drei Patienten mit Nachweis von kolonisierenden Ofloxacin-resistentenPseudomonas aeruginosa entwickelten Pseudomonas-Infektionen. Insgesamt wurden zwölf erworbene Infektionen beobachtet, davon sechs mikrobiologisch dokumentierte Infektionen, die alle durch Ofloxacin-resistente Erreger hervorgerufen wurden (zweiP. aeruginosa, zweiStaphylococcus epidermidis, einAerococcus viridans, einMicrococcus sp.). Die Verträglichkeit der Behandlung war gut. Schwere Nebenwirkungen traten nicht auf. Die gemessenen Konzentrationen von Ofloxacin in Serum und Speichel waren vergleichbar zwischen Patienten und gesunden Kontrollen. Sie waren im Speichel höher als im Serum. Ofloxacin sollte zur Prophylaxe bakterieller Infektionen bei Granulozytopenie als eine mögliche geeignete Alternative zu Trimethoprim-Sulfamethoxazol weiter untersucht werden. Das Risiko einer Koloniserung durch Ofloxacin-resistente Pseudomonaden muß dabei beachtet werden.

This is a preview of subscription content, log in to check access.


  1. 1.

    EORTC International Antimicrobial Therapy Project Group Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. J. Infect. Dis. 150 (1984) 372–379.

  2. 2.

    Kurrle, E.;Dekker, A. W.;Gaus, W.;Haralambie, E.;Krieger, D.;Rozenberg-Arska, M.;De Vries-Hospers, H. G.;Van der Waaij, D.;Wendt, F. (EORTC Gnotobiotic Project Group Writing Committee) Prevention of infection in acute leukemia: a prospective randomized study on the efficacy of two different drug regimens for antimicrobial prophylaxis. Infection 14 (1986) 226–232.

  3. 3.

    Wade, J. C.;De Jongh, C. A.;Newman, K. A.;Crowby, J.;Wiernik, P. H.;Schimpff, S. C. Selective antimicrobial modulation as prophylaxis against infection during granulocytopenia: trimethoprim-sulfamethoxazole vs. nalidixic acid. J. Infect. Dis. 147 (1983) 624–634.

  4. 4.

    Henry, S. H. Chemoprophylaxis of bacterial infections in granulocytopenic patients. Am. J. Med. 76 (1984) 645–651.

  5. 5.

    Bow, E. J.;Louie, T. J.;McNaughton, R. D.;Harding, G. K. M.;Ronald, A. R. Randomized controlled trial comparing trimethoprim-sulfamethoxazole and trimethoprim for infection prophylaxis in hospitalized granulocytopenic patients. Am. J. Med. 76 (1984) 223–233.

  6. 6.

    Wilson, J. M.;Guiney, D. G. Failure of oral trimethoprim/sulfamethoxazole prophylaxis in acute leukemia. Isolation of resistant plasmids from strains of Enterobacteriaceae causing bacteremia. New Engl. J. Med. 306 (1982) 16–20.

  7. 7.

    Rozenberg-Arska, M.;Dekker, A. W.;Verhoef, J. Colistin and trimethoprim-sulfamethoxazole for the prevention of infection in patients with acute non-lymphocytic leukaemia. Decrease of the emergence of resistant bacteria. Infection 11 (1983) 167–169.

  8. 8.

    Kauffman, C.;Liepman, M. K.;Bergman, A. G.;Mioduszewski, J. Trimethoprim/sulfamethoxazole prophylaxis in neutropenic patients. Am. J. Med. 74 (1983) 599–607.

  9. 9.

    Gualtieri, R. J.;Donowitz, G. R.;Kauser, D. L.;Hess, C. E.;Sande, M. A. Double-blind randomized study of prophylactic trimethoprim-sulfamethoxazole in granulocytopenic patients with hematologic malignancies. Am. J. Med. 74 (1983) 934–940.

  10. 10.

    Watson, J. G.;Jameson, B.;Powles, R. L.;McElwain, T. J.;Lawson, D. N.;Judson, I.;Morgenstern, G. R.;Lumley, H.;Kay, H. E. M. Co-trimoxazole versus non-absorbable antibiotics in acute leukaemia. Lancet I (1982) 6–9.

  11. 11.

    Young, L. S. Antimicrobial prophylaxis against infection in neutropenic patients. J. Infect. Dis. 147 (1983) 611–614.

  12. 12.

    Dekker, A. W.;Rozenberg-Arska, M.;Sixma, J.;Verhoef, J. Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukemia. Ann. Int. Med. 95 (1981) 555–559.

  13. 13.

    Kurrle, E.;Bhaduri, S.;Krieger, D.;Pflieger, H.;Heimpel, H. Antimicrobial prophylaxis in acute leukaemia: prospective randomized study comparing two methods of selective decontamination. Klin. Wochenschr. 61 (1983) 691–698.

  14. 14.

    Rozenberg-Arska, M.;Dekker, A. W.;Verhoef, J. Ciprofloxacin for selective decontamination of the alimentary tract in patients with acute leukemia during remission induction treatment: the effect on fecal flora. J. Infect. Dis. 152 (1985) 104–107.

  15. 15.

    Dekker, A. W.;Rozenberg-Arska, M.;Verhoef, J. Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann. Int. Med. 106 (1987) 7–12.

  16. 16.

    Dennig, D.;Fülle, H. H.;Hellriegel, K. P. Chemoprophylaxis of bacterial infections in granulocytopenic patients with ciprofloxacin. Onkologie 10 (1987) 57–58.

  17. 17.

    Winston, D. J.;Ho, W. G.;Nakao, S. L.;Gale, R. P.;Champlin, R. E. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am. J. Med. 80 (1986) 884–890.

  18. 18.

    Schmeiser, T.; Kurrle, E.; Arnold, R.; Bunjes, D.; Wiesneth, M.; Krieger, D.; Heimpel, H.; Heit, W.: Norfloxacin prevents gramnegative infections in bone marrow transplant recipients. 4. International Symposium on Infections in the Immunocompromised Host, Ronneby Brunn, Sweden, June 15–19, 1986 (abstract).

  19. 19.

    Corrado, M.; Brown, K.; Sabbaj, J.: The use of norfloxacin in the prophylaxis of neutropenic patients. In: Ishigami, T. (ed.): Recent Advances in Chemotherapy. Antimicrobial Section 3. Proceedings of the 14th International Congress of Chemotherapy, Kyoto, 1985. University of Tokyo Press, pp. 2115–2116.

  20. 20.

    Karp, J. E.;Merz, W. G.;Hendricksen, C.;Laughon, B.;Redden, T.;Bamberger, B. J.;Bartlett, J. G.;Saral, R.;Burke, P. J. Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia. Ann. Int. Med. 106 (1987) 1–7.

  21. 21.

    Krieger, D.; Vanek, E.; Strehle, R.: Influence of total and selective decontamination on the aerobic and anaerobic gastrointestinal flora in patients with acute leukaemia. In:Sasaki, S. et al. (eds.): Recent Advances in Germfree Research. Tokai University Press, 1981, 715–718.

  22. 22.

    Verhoe, M.;Malerczyk, V.;Dagrosa, E. E.;Korn, A. Dose linearity and other pharmacokinetics of ofloxacin, a new, broad-spectrum antimicrobial agent. Pharmatherapeutica 4 (1985) 376–382.

  23. 23.

    Edlung, C.;Bergan, T.;Josefsson, K.;Solberg, R.;Nord, C. E. Effect of norfloxacin on human oropharyngeal and colonic microflora and multiple-dose pharmacokinetics. Scand. J. Infect. Dis. 19 (1987) 113–121.

  24. 24.

    Pecquet, S.;Andrémont, A.;Tancrède, C. Selective antimicrobial modulation of the intestinal tract by norfloxacin in human volunteers and in gnotobiotic mice associated with a human fecal flora. Antimicrob. Agents Chemother. 29 (1986) 1047–1052.

  25. 25.

    Holt, H. A.;Lewis, D. A.;White, L. O.;Bastable, S. Y.;Reeves, D. S. Effect of oral ciprofloxacin on the faecal flora of healthy volunteers. Eur. J. Clin. Microbiol. 5 (1986) 5201–5205.

  26. 26.

    Brumfitt, W.;Franklin, I.;Grady, D.;Hamilton-Miller, J. M. T.;Iliffe, A. Changes in the pharmacokinetics of ciprofloxacin and fecal flora during administration of a 7-day course to human volunteers. Antimicrob. Agents Chemother. 26 (1984) 757–761.

  27. 27.

    Lockley, M. R.;Wise, R.;Dent, J. The pharmacokinetics and tissue penetration of ofloxacin. J. Antimicrob. Chemother. 14 (1984) 647–652.

  28. 28.

    Chida, T.;Shiboaka, H.;Ishizuka, I.;Nakaya, R. The effect of DL-8280, a new antibacterial agent of pyridone-carboxylic acid derivative, on human fecal flora. Chemotherapy (Tokyo) 32 (Suppl. 1) (1984) 109–117.

  29. 29.

    Cohen, J.;Donnelly, J. P.;Worsley, A. M.;Catovsky, D.;Goldman, J. M.;Galton, D. A. G. Septicemia caused by viridans streptococci in neutropenic patients with leukemia. Lancet II (1983) 1452–1454.

  30. 30.

    Brown, A. E. Neutropenia, fever and infection. Am. J. Med. 76 (1984) 421–428.

  31. 31.

    Kern, W.;Kurrle, E.;Vanek, E. High risk of streptococcal septicemia after high dose cytosine arabinoside treatment for acute myelogenous leukemia. Klin. Wochenschr. 65 (1987) 773–780.

  32. 32.

    Hensele, J.;Bostrom, B.;Weisdorf, D.;Ramsay, N.;McGlave, P.;Kersey, J. Streptococcal sepsis in bone marrow transplant patients Lancet I (1984) 393.

Download references

Author information

Correspondence to Dr. med. W. Kern.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kern, W., Kurrle, E. & Vanek, E. Ofloxacin for prevention of bacterial infections in granulocytopenic patients. Infection 15, 427–432 (1987). https://doi.org/10.1007/BF01647222

Download citation


  • Ofloxacin
  • Aplastic Anemia
  • Acute Leukemia
  • Hairy Cell Leukemia
  • Blast Crisis